Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

Given its solid prospects, Pediatrix Medical currently carries a Zacks Rank #2 (Buy).

Where Do Estimates for MD Stand?

The Zacks Consensus Estimate for Pediatrix Medical’s 2026 earnings is pegged at $2.28 per share, indicating an 11.7% year-over-year rise. In the past seven days, it has witnessed two upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $2 billion for 2026.

The company beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 17.4%.

MD’s Growth Drivers

Pediatrix Medical’s same-unit revenues from net reimbursement-related factors rose 4% year over year in the second quarter of 2026, driven by improved cash collections, a favorable payer mix and higher patient acuity. Commercial and other non-government payors’ share of services also increased 135 basis points year over year, while higher acuity, particularly in neonatology, is expected to continue supporting pricing.

Pediatrix Medical is expanding its telehybrid care capabilities to complement its physical services nationwide. The initiative spans maternal-fetal medicine (MFM), neonatology, retinopathy, neurology and infectious disease. Its network includes more than 170 MFM physicians and more than 360 NICUs across 32 states, providing a broad base for extending virtual care into underserved markets.

Pediatrix Medical is also increasing its OB hospitalist presence by leveraging relationships with more than 400 hospitals. The company has added leadership dedicated to expanding both OB hospitalist and telehybrid medicine operations. This combination can deepen its hospital partnerships while supporting further expansion across women’s healthcare services.

Recent acquisitions contributed to 2.1% year-over-year growth in non-same-unit activity in the second quarter of 2026, helping total revenues rise 4% to $487.8 million. Pediatrix Medical continues to evaluate opportunities across the women’s and children’s healthcare market, with larger transactions potentially supported by joint venture and capital partners.

Its disciplined capital deployment is reflected in its strong return on invested capital (ROIC) of 11.6%, above the industry average of 6.6%, highlighting efficient capital allocation and value creation. During the first half of 2026, the company repurchased 2.8 million shares for $61.7 million. As of June 30, 2026, $104.5 million was available under the buyback program.

MD: Risks to Watch

However, there are some factors that investors should keep a careful eye on.

Pediatrix Medical continues to operate with elevated leverage, with net debt of $584.2 million substantially exceeding its $288.9 million cash balance as of June 30, 2026. The high debt load increases interest expense sensitivity and constrains financial flexibility. Its total debt-to-EBITDA ratio of 2.43X is broadly in line with the industry average, limiting the company’s capacity to absorb earnings volatility or pursue growth initiatives without additional balance sheet strain.

Other Stocks to Consider

Some other top-ranked stocks in the Medical space are BrightSpring Health Services, Inc. BTSG, Globus Medical, Inc. GMED and Centene Corporation CNC, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.78 per share has witnessed five upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.2 billion, suggesting 18.1% year-over-year growth.

The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past seven days, against no movement in the opposite direction. GMED Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.

The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research